Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.93 |
| ▸ | MEN1 | O00255 | 1/20 | 0.87 |
| ▸ | TP53 | P04637 | 1/20 | 0.87 |
| ▸ | MAPT | P10636 | 1/20 | 0.87 |
| ▸ | MTOR | P42345 | 1/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.87 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29669968 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| SCHEMBL29368417 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| SCHEMBL5088067 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| SCHEMBL1155582 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| Nonivamide SCHEMBL81939 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| SCHEMBL8373082 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| SCHEMBL1155739 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| SCHEMBL679954 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| SCHEMBL2400979 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| Nonivamide SCHEMBL29425552 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190038573-A1 | ION CHANNEL ACTIVATORS AND METHODS OF USE | CLIFF-CARTWRIGHT CORPORATION | 2019-02-07 | — | — | US | disclosed |
| EP-3131541-A1 | ION CHANNEL ACTIVATORS AND METHODS OF USE | Flex Pharma, Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20170042834-A1 | ION CHANNEL ACTIVATORS AND METHODS OF USE | CLIFF-CARTWRIGHT CORPORATION | 2017-02-16 | — | — | US | disclosed |
| WO-2015160843-A1 | ION CHANNEL ACTIVATORS AND METHODS OF USE | FLEX PHARMA, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
| US-7034058-B2 | Anti-tumor pharmaceutical composition comprising N-vanillyl fatty acid amide | KUREHA CORPORATION (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20040110844-A1 | Anti-tumor pharmaceutical composition comprising N-vanillyl fatty acid amide | KUREHA CHEMICAL INDUSTRY COMPANY, LIMITED | 2004-06-10 | — | — | US | disclosed |
| EP-1426047-A1 | Anti-tumour pharmaceutical composition comprising N-vanillyl fatty acid amide | Kureha Chemical Industry Company, Limited (JP) | 2004-06-09 | — | — | EP | disclosed |
| US-6022718-A | MAKING A FATTY ACID COMPOUND USEFUL IN THE FOOD INDUSRTY FOR DIETETICS AND HEALTH FOOD; REACTING FATTY ACID WITH CAPSAICIN AND LIPASE TO MAKE FATTY ACID AMIDE | MARUZEN PHARMACEUTICALS CO., LTD. (JP) | 2000-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110844-A1 | Anti-tumor pharmaceutical composition comprising N-vanillyl fatty acid amide | ELOVL1, TRPV1, ELOVL5 | CYP1A2 2164/4885CYP3A4 3000/4885CYP2D6 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.